Citius Oncology, a subsidiary of Citius Pharmaceuticals, is on the cusp of launching LYMPHIR™, their recently FDA-approved immunotherapy for adults battling relapsed or refractory cutaneous T-cell lymphoma (CTCL). This groundbreaking product, a recombinant fusion protein, works by precisely targeting and eliminating cancerous T-cells and immunosuppressive regulatory T-cells through a unique mechanism involving IL-2 receptor binding and subsequent cellular disruption. The company has diligently prepared for this pivotal launch, ensuring a robust supply chain with a 60-month product shelf life, securing broad distribution through top-tier logistics partners, and engaging extensively with Key Opinion Leaders and patient advocacy groups. With a strategic commercial and marketing plan, including the use of AI for targeted outreach, and strong market access positioning through NCCN guideline inclusion and a permanent J-code, Citius Oncology is set to introduce LYMPHIR™ in the U.S. in the second half of 2025, offering a much-needed treatment option for CTCL patients who currently lack curative therapies.